AccuStem Sciences, Inc. (ACUT) Fair Value 2026

ACUT · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.8 /10

32 fundamental signals · 0 models active

Value Trap Risk

WARN (53/100)

Quick Summary — As of 2026-08-27, AccuStem Sciences, Inc. (ACUT) trades at $0.15. QOC: 3.8/10. Value Trap Risk: 53/100 (WARN). 0/13 models active.

Key Facts

Ticker
ACUT
Price
$0.15
Quality Score
3.8/10
Value Trap Risk
53/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 53 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give ACUT?

0 Intrinsic Value Models vs. Current Price ($0.15)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is AccuStem Sciences, Inc. (ACUT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, AccuStem Sciences, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About ACUT?

0 of 13 models are currently active for ACUT. See which stocks rank higher →

How Does ACUT Rank in Biotechnology?

Among 620 Biotechnology stocks, ACUT ranks #546 by Quality of Company score. CirclFi's QOC score of 3.8/10 evaluates 32 fundamental signals. A score of 3.8 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, AccuStem Sciences, Inc. competes in an environment where cash runway (months) often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is ACUT a Value Trap?

CirclFi's Value Trap algorithm assigns ACUT a score of 53/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for AccuStem Sciences, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, AccuStem Sciences, Inc. is rated at 3.8/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ACUT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy AccuStem Sciences, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

BCLIBrainstorm Cell Therapeutics Inc.QOC 3.8ESLAEstrella Immunopharma, Inc.QOC 3.8BSEMBioStem Technologies, Inc.QOC 3.8OMEROmeros CorporationQOC 3.8RNAZTransCode Therapeutics, Inc.QOC 3.9VORVor Biopharma Inc.QOC 3.8TVTXTravere Therapeutics, Inc.QOC 6.6DNLIDenali Therapeutics Inc.QOC 5.4ENGNenGene Therapeutics Inc.QOC 4.7EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: BCLI · ESLA · BSEM · OMER · RNAZ · VOR · TVTX · DNLI · ENGN · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ACUT?

5 companies across all industries closest to ACUT’s Quality of Company score of 3.8/10.

JFILJubilant Flame International, Ltd.QOC 3.8BRQLDynamic Aerospace SystemsQOC 3.8SPQSSparxx CorporationQOC 3.8RNGCRanger Gold Corp.QOC 3.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: JFIL · BRQL · SPQS · RNGC · NVDA

Where Does ACUT Sit in CirclFi's Biotechnology Rankings?

ACUT is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About AccuStem Sciences, Inc.’s Valuation?

What is AccuStem Sciences, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for AccuStem Sciences, Inc. (ACUT). The Quality of Company score is 3.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ACUT overvalued or undervalued right now?

At $0.15, 0 of 0 active models suggest ACUT may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits AccuStem Sciences, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 3.8 mean for ACUT?

AccuStem Sciences, Inc.'s QOC of 3.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on ACUT?

CirclFi analyzes ACUT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is ACUT a value trap in 2026?

AccuStem Sciences, Inc.'s Value Trap score is 53/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns AccuStem Sciences, Inc. (ACUT) a Quality of Company score of 3.8/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/ACUT/ · Methodology
Primary sources for this ACUT valuation
  • Financial statements: AccuStem Sciences, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001850767) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ACUT as of ; valuations recomputed .